NeRRe hopes to advance cough candidate despite Phase II miss

While NeRRe's orvepitant missed the primary endpoint of the Phase IIb VOLCANO-2 trial, the company believes the trial's patient-reported outcomes support advancement of the refractory chronic cough therapy into Phase III testing.